已选(0)清除
条数/页: 排序方式:
|
| Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis 期刊论文 NATIONAL SCIENCE REVIEW, 2022, 卷号: 9, 期号: 7, 页码: 15 作者: Jin, Yujuan; Zhao, Qiqi; Zhu, Weikang; Feng, Yan; Xiao, Tian
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:23/0  |  提交时间:2023/02/07
|
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文 JOURNAL OF HEPATOLOGY, 2019, 卷号: 70 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:61/0  |  提交时间:2019/12/05 |
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:50/0  |  提交时间:2019/12/05 |
| 2017年上海市细菌耐药性监测 期刊论文 中国感染与化疗杂志, 2019, 卷号: 19, 期号: 2 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:46/0  |  提交时间:2019/12/05
|
| THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:39/0  |  提交时间:2019/12/05 |
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:41/0  |  提交时间:2019/12/05 |
| THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:33/0  |  提交时间:2019/12/05 |
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:32/0  |  提交时间:2019/12/05 |
| 2017年上海市细菌耐药性监测 期刊论文 中国感染与化疗杂志, 2019, 卷号: 19, 期号: 2 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:30/0  |  提交时间:2019/12/06
|
| Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 期刊论文 HEPATOLOGY, 2018, 卷号: 68 作者:
![](/themes/default/image/downing1.png) 收藏  |  浏览/下载:23/0  |  提交时间:2019/12/05 |